Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims align with the provided label excerpt (indication for hypokalemia treatment/prophylaxis; need for non-empty-stomach administration for extended-release tablets). Multiple other claims are not supported or cannot be verified from the provided label excerpts (e.g., meaning of “SA”, formulation-release expectations, dosing frequency, crushing/chewing restrictions, and symptoms of hyperkalemia).
Category Scores
Accurate Statements
Potassium chloride is a salt supplement used to prevent or treat low potassium (hypokalemia).
Supported by provided Indications excerpt: “indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis...” (Section 1).
Potassium chloride SA products are generally prescribed for low blood potassium levels (hypokalemia).
Consistent with Section 1 indication for treatment/prophylaxis of hypokalemia, though the label excerpt does not define “SA”.
Potassium chloride SA products are generally prescribed for situations that cause potassium loss (for example, certain diuretics).
Partially aligned: Section 1 indicates use in patients “for whom dietary management ... or diuretic dose reduction is insufficient,” which implies association with diuretic-related hypokalemia risk. The claim provides an example (“certain diuretics”) not explicitly detailed in the excerpt.
Potassium chloride extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation.
Supported by provided Warning/Precaution excerpt: “should not be taken on an empty stomach because of its potential for gastric irritation” (Sections 5 and 5.1 cross-reference to 2.1).
Unsupported Statements
Some products labeled with the abbreviation “SA” signal a sustained- or slow-release formulation.
Provided label excerpts do not define “SA” or link it to sustained/slow release.
Sustained- or slow-release potassium formulations are intended to release potassium more gradually than immediate-release tablets.
The provided excerpts describe extended-release tablets and GI contact duration, but do not explicitly state release-rate intent vs immediate-release.
Potassium chloride SA products are generally prescribed to prevent recurrence when someone is at ongoing risk for low potassium.
The label excerpt supports prophylaxis, but does not describe “ongoing risk for recurrence” phrasing or that recurrence prevention is the usual practice.
Sustained-release potassium products are usually taken so that potassium is released over time.
No explicit statement about timing of release is included in the provided excerpts.
Sustained-release potassium products can affect dosing timing, often requiring fewer doses per day than immediate-release.
No dosing-frequency comparison between formulations is present in the provided excerpts.
Many sustained-release potassium tablets must not be crushed or chewed because this can release the drug too quickly.
The provided excerpts do not mention crushing/chewing restrictions for extended-release tablets.
Taking extra potassium without medical advice can be dangerous because too much potassium can be dangerous.
No content about hyperkalemia risk or harm from excess potassium is included in the provided excerpts.
Changes to the dosing form (like crushing) should be avoided unless a clinician or pharmacist confirms it’s allowed for that specific brand.
No guidance on changing dosing form/crushing for extended-release tablets is present in the provided excerpts.
High potassium can present with symptoms such as severe weakness or abnormal heart rhythm.
No hyperkalemia symptom list is included in the provided excerpts.
“SA” can be brand- or country-specific and may indicate a particular release technology.
The provided excerpts do not discuss “SA” being brand/country-specific or indicating a specific release technology.
Contradictions
Low
AI Statement
Potassium chloride SA products are generally prescribed to prevent recurrence when someone is at ongoing risk for low potassium.
Label Reference
No direct contradiction found; classified as unsupported rather than contradictory because Section 1 supports prophylaxis but does not use the same phrasing. No contradictory label text provided.
Important Omissions
Contraindication: potassium chloride is contraindicated in patients on triamterene and amiloride.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant claims (e.g., crushing/chewing restrictions, hyperkalemia dangers/symptoms, and excess dosing cautions) are not supported by the provided label excerpts. Additionally, the key contraindication with triamterene/amiloride is omitted from the claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/uncorroborated claims about “SA” meaning, release behavior, dosing frequency comparisons, crushing/chewing guidance, and hyperkalemia symptoms; omission of the stated contraindication (triamterene/amiloride).
Suggested Improvement
Limit claims to what is supported by the provided label excerpts (indication for treatment/prophylaxis of hypokalemia; do not take on an empty stomach; mention the contraindication with triamterene/amiloride). Remove or rephrase unsupported formulation (“SA”) and administration/dosing-form-change assertions unless additional label text is provided.